TsuyukiRTBeahmNPOkadaHAl HamarnehY. Pharmacists as accessible primary health care providers: review of the evidence. Can Pharm J (Ott)2018;151(1):4-5.
2.
TsuyukiRTMontagueDThompsonARabiD. Use of Hypertension Canada/Canadian Hypertension Education Program (CHEP) guidelines in teaching in Canadian pharmacy schools (abstract). Can Pharm J (Ott)2017;150(4):S71.
3.
SantschiVTsuyukiRTParadisG. Evidence for pharmacist care in the management of hypertension. Can Pharm J (Ott)2015;148(1):13-16.
4.
TsuyukiRTHouleSKDCharroisTLet al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation2015;132:93-100.
5.
MarraCJohnstonKSantschiVTsuyukiRT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott)2017;150(3):184-197.
6.
KoshmanSLCharroisTLSimpsonSHet al. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med2008;168:687-694.
7.
TsuyukiRTAl HarmarnehYNJonesCAHemmelgarnBR. Effectiveness of community pharmacist prescribing and care on cardiovascular risk reduction: randomized controlled RxEACH trial. J Am Coll Cardiol2016;67:2846-2854.
8.
BeahmNPSmythDJTsuyukiRT. Outcomes of urinary tract infection management by pharmacists (RxOUTMAP): a study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community. Can Pharm J (Ott) 2018. Available: https://doi.org/10.1177/1715163518781175 (accessed Jun. 3, 2018).
9.
Al HamarnehYCharroisTLewanczukRTsuyukiRT. Pharmacist intervention for glycemic control in the community (The RxING Study). BMJ Open2013;3:e003154.
10.
Al HamarnehYNTsuyukiRTLambSet al. Pharmacists’ expanded scope of practice improved cardiovascular risk, but what do patients think? A substudy of the RxEACH study. Can Pharm J (Ott)2018;151(4):In press.
11.
TsuyukiRTBergAKhanNA. The ultimate opportunity for advancing pharmacy practice. Can Pharm J (Ott)2017;150(4):225-226.